Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y (NPY) in phenylpropranolamine-mediated appetite suppression

Peptides. 2004 Dec;25(12):2155-61. doi: 10.1016/j.peptides.2004.08.015.

Abstract

Phenylpropanolamine (PPA) is an appetite suppressant. The mechanism for the anorectic effect of PPA has been attributed to its action on the site of hypothalamic paraventriculum. Neuropeptide Y (NPY) is an appetite stimulant that is widely distributed in the site of hypothalamus. It is not clear whether hypothalamic NPY is involved in the anorectic action of PPA. This study was aimed to investigate the mechanism underlying the involvement of NPY gene in the anorectic action of PPA. Results revealed that PPA treatment in rats could decrease both NPY content and mRNA level in the hypothalamus. In addition, the expression of NPY immunoreactivity following PPA treatment was decreased in areas of hypothalamic arcuate nucleus, paraventricular nucleus and periventricular area using immunohistochemical staining, suggesting an involvement of NPYergic pathway in the action of PPA anorexia. Our results provided immunohistochemical and genomic evidence to suggest that PPA might reduce feeding by altering NPY gene expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Appetite / drug effects*
  • Appetite Depressants / pharmacology*
  • Eating / drug effects
  • Gene Expression / drug effects
  • Hypothalamus / chemistry
  • Hypothalamus / drug effects
  • Immunohistochemistry
  • Male
  • Neurons / drug effects
  • Neuropeptide Y / physiology*
  • Phenylpropanolamine / pharmacology*
  • Rats
  • Rats, Wistar

Substances

  • Appetite Depressants
  • Neuropeptide Y
  • Phenylpropanolamine